Inhibition of intra‐ and extra‐cellular Tat function and HIV expression by pertussis toxin B‐oligomer

C. Rizzi,M. Alfano,A. Bugatti,M. Camozzi,G. Poli,M. Rusnati
DOI: https://doi.org/10.1002/eji.200324142
2004-02-01
European Journal of Immunology
Abstract:HIV‐1‐transactivating factor Tat contributes to virus replication and to the onset of AIDS‐associated pathologies by targeting different infected and uninfected cell types. We previously demonstrated that the B‐oligomer of pertussis toxin (PTX‐B) inhibits HIV infection and replication in primary T cells and macrophages and Tat‐dependent HIV‐1 long terminal repeat (LTR) transactivation inT lymphoid Jurkat cells. Here we demonstrate that PTX‐B inhibits Tat‐dependent NF‐κB activation and HIV‐1 LTR‐transactivation in non‐permissive epithelial HL3T1 cells in a phosphatidylinositol 3′‐kinase‐dependent way. PTX‐B exerts its inhibition both when Tat is produced endogenously in transfected cells and in cells incubated with the extracellular Tat protein. In this latter case, PTX‐B does not interfere with extracellular Tat uptake by cells. PTX‐B inhibited also interleukin‐8 secretion and virus expression stimulated in chronically infected U1 promonocytic cells by intra‐ and/or extracellular Tat. The genetically modified holotoxin PT‐9 K/129G retains the capacity to inhibit Tat transactivating activity and HIV replication in both HIV‐permissive and non‐permissive cells. Inconclusion, PTX‐B acts as a "pleiotropic" inhibitor of Tat, and this may significantly contribute to the broad spectrum of anti‐HIV‐1 effects exerted by PTX‐B in different cell types, and suggests PTX‐B and its derivatives as prototypic for the development of anti‐Tat drugs.
What problem does this paper attempt to address?